Rapid HIV-1 tests
This article was originally published in The Gray Sheet
CLIA-waived status for the tests is being pursued by an HIV coalition supported by the President's Advisory Council on HIV/AIDS and the Congressional Black Caucus. "We call on [FDA and CMS] to release HIV rapid tests with CLIA waiver immediately," the groups state in an Oct. 24 release, arguing that state regulations provide sufficient safeguards. OraSure received a May "approvable" letter from FDA for its OraQuick rapid HIV test, requiring resolution of "specific validation and control issues" before agency sign-off (1"The Gray Sheet" June 24, 2002, p. 22)...
You may also be interested in...
OraSure Technologies' license of non-exclusive rights to certain test strip technology patents from Abbott appears to clear the way for a U.S. launch of OraSure's OraQuick rapid HIV-1 test, pending FDA approval
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.